Gelteq (GELS) Current Deferred Revenue (2024)
Gelteq (GELS) posted quarterly Current Deferred Revenue of $77627.3 for Q4 2024, down 6.04% quarter-over-quarter from $82614.7 in Q2 2024.
Gelteq (GELS) Current Deferred Revenue (2024) Analysis & Trends
Gelteq's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $77627.3 for Q4 2024.
- In Q4 2024, Current Deferred Revenue changed N/A year-over-year to $77627.3; the TTM figure through Dec 2024 stood at $77627.3 (changed N/A YoY), while the FY2024 annual figure was $82614.7, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2024 stood at $77627.3, down from $82614.7 in the prior quarter.
- The five-year high for Current Deferred Revenue was $82614.7 in Q2 2024, with the low at $77627.3 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Gelteq | 5.90 Mn | 5.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 77,627.26 |
| Jun 30, 2024 | 82,614.65 |